Lilly's retatrutide delivers more than double Ozempic's weight loss in Phase 3 trial
LLY•Eli Lilly said retatrutide delivered greater blood sugar reductions and more than double the weight loss of Ozempic’s highest approved dose in a Phase 3 trial of adults with type 2 diabetes, meeting all key endpoints. Gastrointestinal problems were the most common adverse events, and discontinuations due to adverse events were higher with retatrutide.
1. Trial results
Eli Lilly announced positive Phase 3 results for retatrutide versus Ozempic in adults with type 2 diabetes. The investigational drug delivered greater blood sugar reductions and more than double the weight loss of Ozempic’s highest approved dose, meeting all key trial endpoints.
2. Safety and next steps
Gastrointestinal problems were the most common adverse events, and treatment discontinuations due to adverse events were higher with retatrutide. The drug has not received regulatory approval anywhere; detailed results will be presented at a future medical meeting and published.
